{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:57:26Z","timestamp":1768265846033,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Region Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clinbiochem.2025.110913","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T12:31:09Z","timestamp":1741955469000},"page":"110913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Therapeutic drug monitoring of levetiracetam \u2013 Is dried blood spot sampling suitable?"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6832-6638","authenticated-orcid":false,"given":"Camilla","family":"Linder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela Oana","family":"Romanitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislav","family":"Beniaminov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Ekheden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2025.110913_b0005","first-page":"338","article-title":"A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants","volume":"32","author":"Guthrie","year":"1963","journal-title":"J. Am. Acad. Pediatr."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0010","doi-asserted-by":"crossref","DOI":"10.1007\/s13318-023-00846-4","article-title":"Dried blood spots\u2014a platform for therapeutic drug monitoring (TDM) and drug\/disease response monitoring (DRM)","author":"Zailani","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/FTD.0000000000000884","article-title":"Microsampling devices for routine therapeutic drug monitoring-are we there yet?","volume":"43","author":"Morgan","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0020","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/epd2.20069","article-title":"Pharmacological aspects of antiseizure medications: From basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring","author":"Johannessen Landmark","year":"2023","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0030","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0035","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1212\/WNL.0000000000201348","article-title":"Association of levetiracetam concentration with seizure frequency in pregnant women with epilepsy","volume":"100","author":"Schelhaas","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2025.110913_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0167433","article-title":"Cost evaluation of dried blood spot home sampling as compared to conventional sampling for therapeutic drug monitoring in children","volume":"11","author":"Martial","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2025.110913_b0045","first-page":"1","article-title":"Parents\u2019 perspectives on dried blood spot self-sampling from children with epilepsy: A mixed-method study","volume":"00","author":"Linder","year":"2020","journal-title":"Acta Paediatr Int. J. Paediatr."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation od dried blood spot based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0055","unstructured":"European Medicines Agency, ICH Guideline M10 on Bioanalytical Method Validation, Sci. Med. Heal. 44 (2019) 57. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf%0Ahttps:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation#current-version-section (accessed July 15, 2024)."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0060","unstructured":"European Medicines Agency, Guideline on bioanalytical method validation, (2011). www.ema.europa.eu (accessed July 15, 2024)."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0065","unstructured":"FDA, Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Contains Nonbinding Recommendations, (2018). http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htmand\/orhttp:\/\/www.fda.gov\/AnimalVeterinary\/GuidanceComplianceEnforcement\/GuidanceforIndustry\/default.htm (accessed July 13, 2024)."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchromb.2013.02.005","article-title":"A simple bioanalytical method for the quantification of antiepileptic drugs in dried blood spots","volume":"923\u2013924","author":"Shah","year":"2013","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.clinbiochem.2025.110913_b0075","first-page":"1","article-title":"Analytical and clinical validation of an LC-MS\/MS method for carbamazepine, lamotrigine and levetiracetam in dried blood spots","volume":"0","author":"Besten-Bertholee","year":"2023","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0080","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/FTD.0000000000000890","article-title":"Therapeutic drug monitoring of lamotrigine, lacosamide, and levetiracetam in dried capillary blood-determination of conversion factors for serum-based reference ranges","volume":"43","author":"Klimpel","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0085","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/FTD.0000000000000605","article-title":"Dried blood spot self-sampling by guardians of children with epilepsy is feasible","volume":"41","author":"Linder","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/FTD.0000000000000600","article-title":"LC-MS\/MS-based quantification of 9 antiepileptic drugs from a dried sample spot device","volume":"41","author":"D\u02bcUrso","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bmc.5130","article-title":"Development and validation of an LC\u2013MS\/MS method for relevant drugs in epilepsy patients using dried blood spots","volume":"35","author":"M\u00f6ller","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0100","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.4155\/bio.10.159","article-title":"Pharmacokinetic considerations as to when to use dried blood spot sampling","volume":"2","author":"Emmons","year":"2010","journal-title":"Bioanalysis"},{"key":"10.1016\/j.clinbiochem.2025.110913_b0105","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/10408363.2017.1343796","article-title":"Capillary blood for point of care testing","volume":"54","author":"Tang","year":"2017","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jchromb.2017.11.005","article-title":"Carbamazepine, lamotrigine, levetiracetam and valproic acid in dried blood spots with liquid chromatography tandem mass spectrometry; method development and validation","volume":"1072","author":"Linder","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed Life Sci."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0115","unstructured":"ARK, Levetiracetam Assay, ARK Dign. Fremont, CA (2017). http:\/\/ark-tdm.com\/products\/epilepsy\/levetiracetam\/pdfs\/ARK_Levetiracetam_Assay_Rev03_February_2017.pdf (accessed February 18, 2019)."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4155\/bio-2023-0018","article-title":"A validated method for the determination of hematocrit in dried blood spots using image analysis","volume":"15","author":"Barroso","year":"2023","journal-title":"Bioanalysis"},{"key":"10.1016\/j.clinbiochem.2025.110913_b0125","first-page":"709","article-title":"A new biometrical procedure for testing the equality of measuremments from two different analytical methods. Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part 1","volume":"21","author":"Passing","year":"1983","journal-title":"J. Clin. Chem. Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0130","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(95)91748-9","article-title":"Comparing methods of measurement\u00a0: why plotting difference against standard method is misleading","volume":"346","author":"Bland","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2025.110913_b0135","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00228-003-0655-6","article-title":"Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers","volume":"59","author":"Strolin Benedetti","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0140","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/FTD.0000000000000652","article-title":"Volumetric absorptive microsampling: A new sampling tool for therapeutic drug monitoring of antiepileptic drugs","volume":"41","author":"D\u2019Urso","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0145","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jpba.2018.10.010","article-title":"Is the hematocrit still an issue in quantitative dried blood spot analysis?","volume":"163","author":"Velghe","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110913_b0150","first-page":"46","article-title":"Revolutionizing blood collection\u00a0: innovations, applications , and the potential of microsampling technologies for monitoring metabolites and lipids","volume":"14","author":"Bossi","year":"2024","journal-title":"Multidiscip. Digit. Publ. Institute, Metab."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0155","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/FTD.0000000000000605","article-title":"Dried blood spot self-sampling by guardians of children with epilepsy is feasible: comparison with plasma for multiple antiepileptic drugs","volume":"41","author":"Linder","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0160","first-page":"307","article-title":"A proposal for strength-of-agreement criteria for Lin\u2019s Concordance Correlation Coefficient","volume":"45","author":"Lin","year":"2005","journal-title":"NIWA Client Rep."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115539","article-title":"Evaluation of dried blood spots as an alternative sampling strategy for 5-fluorouracil monitoring: From method development to clinical application","volume":"235","author":"da Silva","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.clinbiochem.2025.110913_b0170","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4155\/bio.14.156","article-title":"Spot them in the spot\u00a0: analysis of abused substances using dried blood spots","volume":"6","author":"Sadones","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1016\/j.clinbiochem.2025.110913_b0175","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/201918","article-title":"Potential of dried blood self-sampling for cyclosporine c(2) monitoring in transplant outpatients","author":"Leichtle","year":"2010","journal-title":"J. Transplant."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912025000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912025000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:50:44Z","timestamp":1763664644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912025000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":35,"alternative-id":["S0009912025000426"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.110913","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring of levetiracetam \u2013 Is dried blood spot sampling suitable?","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.110913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The Canadian Society of Clinical Chemists.","name":"copyright","label":"Copyright"}],"article-number":"110913"}}